secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001193125-25-021345
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics appoints Hans-Juergen Woerle, M.D. to board, designated by Nestlé
--------------------------------------------------------------------------------

- Board expanded to nine directors; Woerle appointed as Class III director effective Feb 4, 2025.
- Woerle is Chief Medical Officer and Chief Scientific Officer at Nestlé Health Science since Nov 2018.
- Designated by Nestlé under Securities Purchase Agreement requiring Nestlé to hold ≥10% of shares.
- Initial option grant of 120k shares at $0.8056 strike, vesting over 4 years; annual retainer $45k plus $7.5k for committee service.
- Woerle also serves on Enterome SA board and previously Cerecin Inc. board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525021345/0001193125-25-021345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525021345/d890486d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-021345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer